• Bruno A Grassi, Camila Hernández, Mariana Boncompte, Camila Henríquez, Nicole L'huillier, Francisca Miranda, Katica Vrsalovic, and Valentina Rosales.
• Departamento de Nutrición, Diabetes y Metabolismo, Pontificia Universidad Católica de Chile, Santiago, Chile.
• Rev Med Chil. 2022 Oct 1; 150 (10): 133413411334-1341.

BackgroundThe use of glucose lowering agents with favorable weight profile is a growing practice in Diabetology.AimTo characterize medication combinations in patients with type 2 Diabetes (T2D) and their effect on metabolic control.Material And MethodsReview of medical records of 249 outpatients with T2D with a median age of 66 years, cared for at a medical network. Clinical characteristics, glycated hemoglobin (HbA1c), details of Diabetes treatment (types of drugs or insulin), renal function, lipids and B12 vitamin levels were registered.ResultsThe median disease duration was 16 years. The most recent HbA1c was 7.4%. No patient was using sulfonylureas, 45 were using Dipeptidyl peptidase 4 inhibitors, 113 were using Sodium-glucose Cotransporter-2 (SGLT2i) Inhibitors, 21 used Glucagon-like Peptide-1 Receptor Agonists (GLP1ra), 158 used basal insulin and 61 on basal plus bolus insulin. The use of SGLT2i or GLP1ra was associated with a metabolic control similar to those patients not using them, while patients on rapid insulin had a significantly worse metabolic control and a tendency to greater body mass index. The use of basal insulin and rapid insulin was significantly associated with more hypoglycemia events.ConclusionsThe use of SGLT2i and GLP1ra in patients with T2D is associated with better metabolic control than rapid insulin with less risk of hypoglycemia. The use of these therapies should be prioritized in the future.

25 keywords...

hide…